Record number:
921
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for urothelial carcinoma (Council of Europe, 2022):
No literature exists regarding newly diagnosed urothelial cancer and organ donation. Therefore, the highest caution is recommended, and the advice of a urologist may be sought in assessing the individual donor tumour transmission risk. National recommendations should be followed since they vary in accepting these tumours. Urothelial cancer in the donor history: Strict follow-up must have been provided after primary diagnosis because these tumours may be multicentric and tend to recur, with a need for repeated cystoscopy and TUR-B, and for restaging. Kidney transplantation will be associated with increased risk, but this has not been classified in the literature yet. After a disease-free interval > 5 years, the transmission risk of invasive urothelial cancer will depend on the probability of cure and must be assessed individually before accepting a potential organ donor. No specific recommendations are available from the literature.
Time to detection:
14 months
Alerting signals, symptoms, evidence of occurrence:
Team alerted that one of the two kidney recipients from the same donor has developed an urothelial tumor 9 months after transplantation. Imaging tests performed monthly in the liver-transplanted patient revealing no abnormalities. Fourteen months after transplantation, episodes of fever, with imaging and liver biopsy showing a clear cell tumor of urothelial origin in the graft.
Demonstration of imputability or root cause:
More than one recipient affected: one kidney and liver recipients (the other kidney recipient is disease-free in the report)
Keywords:
Suggest references:
AAA